The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
May. 16, 2023

Filed:

Feb. 09, 2019
Applicant:

Astrazeneca Computational Pathology Gmbh, Munich, DE;

Inventor:

Guenter Schmidt, Munich, DE;

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
G16H 50/30 (2018.01); G16B 25/10 (2019.01); G16B 45/00 (2019.01); G16B 20/00 (2019.01); G16B 40/00 (2019.01); G16H 40/63 (2018.01); G01N 33/574 (2006.01); G16H 30/40 (2018.01); G16H 50/20 (2018.01); G16B 40/20 (2019.01); C12Q 1/6886 (2018.01);
U.S. Cl.
CPC ...
G16H 50/30 (2018.01); C12Q 1/6886 (2013.01); G01N 33/57434 (2013.01); G16B 20/00 (2019.02); G16B 25/10 (2019.02); G16B 40/00 (2019.02); G16B 40/20 (2019.02); G16B 45/00 (2019.02); G16H 30/40 (2018.01); G16H 40/63 (2018.01); G16H 50/20 (2018.01); G01N 2570/00 (2013.01); G01N 2800/342 (2013.01); G01N 2800/52 (2013.01); G01N 2800/54 (2013.01); G01N 2800/7028 (2013.01);
Abstract

A method that provides a graphical indication of whether a patient will have cancer recurrence uses univariate and bivariate prognostic features that were generated as part of a minimal spanning tree (MST). The method determines the values of first and second features. A first value is measured by detecting objects in an image of tissue from the cancer patient stained with a protein-specific IHC biomarker. A second value is measured using objects marked with an mRNA-specific probe biomarker detected in the tissue. The first feature is the univariate prognostic feature for cancer recurrence in a cohort of cancer patients. A combination of the first and second features is the bivariate prognostic feature for cancer recurrence in the cohort. The first and second features are elements of the MST. Nodes of the MST represent the univariate features, edges represent the bivariate features, and edge weights represent prognostic significance of bivariate features.


Find Patent Forward Citations

Loading…